Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-11-23
DOI
10.1111/bph.15747
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
- (2021) Frédéric Jaisser et al. Frontiers in Pharmacology
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)
- (2020) Mizuki Takahashi et al. FEBS LETTERS
- Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease
- (2020) George Bakris et al. HYPERTENSION
- Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
- (2020) Ningning Wan et al. JOURNAL OF HUMAN HYPERTENSION
- Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease
- (2020) Hewang Lee et al. BMC Nephrology
- Aldosterone, Inflammation, Immune System, and Hypertension
- (2020) Nathanne S Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
- (2020) Tadakatsu Nakamura et al. Clinical Pharmacology in Drug Development
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
- (2020) Sadayoshi Ito et al. HYPERTENSION RESEARCH
- Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
- (2019) Sadayoshi Ito et al. JOURNAL OF HUMAN HYPERTENSION
- Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction
- (2019) Lan Yao et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
- (2019) Daniel Lavall et al. BIOCHEMICAL PHARMACOLOGY
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
- (2019) Andrew Whittaker et al. CTS-Clinical and Translational Science
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
- (2018) Fredrik Erlandsson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
- (2018) Marco Trevisan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
- (2018) Michael Gerisch et al. DRUG METABOLISM AND DISPOSITION
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
- (2018) Robert M. Carey et al. HYPERTENSION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Coregulators as mediators of mineralocorticoid receptor signalling diversity
- (2017) Peter J Fuller et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
- (2017) Jochen Dutzmann et al. PLoS One
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- The Concise Guide to PHARMACOLOGY 2015/16: Overview
- (2015) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
- (2015) Murray Epstein Lancet Diabetes & Endocrinology
- Endothelial Cell Mineralocorticoid Receptors Regulate Deoxycorticosterone/Salt-Mediated Cardiac Remodeling and Vascular Reactivity But Not Blood Pressure
- (2014) Amanda J. Rickard et al. HYPERTENSION
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors
- (2012) Amy McCurley et al. NATURE MEDICINE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
- (2011) Daniela Fraccarollo et al. CIRCULATION
- Ablation of Mineralocorticoid Receptors in Myocytes But Not in Fibroblasts Preserves Cardiac Function
- (2011) Achim Lother et al. HYPERTENSION
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
- (2011) Jean-Philippe Bertocchio et al. KIDNEY INTERNATIONAL
- SnapShot: Nuclear Receptors I
- (2010) Neil J. McKenna et al. CELL
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
- (2009) S. D. Navaneethan et al. Clinical Journal of the American Society of Nephrology
- Aldosterone Activates NF- B in the Collecting Duct
- (2008) V. Leroy et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now